Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Poised To File Isatuximab In Multiple Myeloma, Going Up Against J&J's Darzalex

Executive Summary

Isatuximab could be the next building block in Sanofi's ambitions to rebuild in oncology. The CD38-targeting antibody extended PFS in relapsed/refractory multiple myeloma in combination with Celgene's Pomalyst and dexamethasone.

Advertisement

Related Content

Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
Myeloma Milestones: Selinexor May Be Next Novel Agent While Established Drugs Expand Indications
Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic
New EU Market Hopefuls Await Their Fate; EMA Re-Adopting Zynteglo Opinion
Darzalex Excites As Potential Grows In Multiple Myeloma
Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
This Isn't The Big One: Darzalex Wins US Approval In First-Line Multiple Myeloma
Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche
Janssen/Genmab Win 1st Anti-CD38 In Multiple Myeloma

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124618

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel